GenoSpace has built a comprehensive platform for genomic and other biomedical data. Its serves research, clinical development, pathology and clinical care customers who work with high-dimensional genomic and other biomedical data.
At GenoSpace, we are digital architects of genomic medicine. GenoSpace has built a comprehensive platform for precision medicine to enable interpretation, analysis, reporting and collaboration on high-dimensional genomic and other biomedical data. With specific applications supporting research, development, pathology and clinical care, many of the most advanced precision medicine organizations are powered by GenoSpace.
GenoSpace has built a comprehensive software platform for genomic medicine. The company leverages a single storage and security platform to deliver a variety of applications and services including reporting, population analytics, clinical trial matching, interactive physician and patient portals, and patient communities. GenoSpace specializes in data integration, modeling, analysis, interpretation, visualization and collaboration. GenoSpace applications serve users at laboratories, health systems, and organizations engaged in research and clinical development, as well as patients.
GenoSpace was founded by John Quackenbush and Mick Correll in 2012 after they realized existing platforms for analyzing genomic information could be greatly improved. John is board chair and Mick is chief executive officer.
John received his PhD in theoretical physics from UCLA in 1990. Following a physics postdoc, he was awarded a 1992 NIH Special Emphasis Research Career Award to work on the Human Genome Project. After two years at the Salk Institute and two years at Stanford University, he moved to The Institute for Genomic Research, pioneering gene expression analysis. He joined the Dana-Farber Cancer Institute and Harvard School of Public Health in 2005 and works on reconstruction of gene networks that drive the development of disease. He received a 2013 White House Open Science Champion of Change award for his work on facilitating genomic data access.Mick Correll
Mick’s more than 15-year career has tracked the path of genomics from basic research to clinical care. Over this time he has held leadership positions in academia and industry, and has developed informatics solutions for pharma/biotech R&D, ag-bio, and academic, government and community healthcare providers. Prior to launching GenoSpace, he and partner John Quackenbush established the Center for Cancer Computational Biology at the Dana-Farber Cancer Institute. Mick began his career at Lion Bioscience Research Inc. and UK-based informatics provider InforSense. Mick earned a BS in Computer Science and BA in Molecular Biology from the University of Colorado at Boulder.
Market opportunity (in your particular space–numbers, competitors, etc. are helpful)
The market for interpreting and analyzing molecular and other biomedical data is a multi-billion dollar component of the broader molecular diagnostics and applicable life science research markets—each of which represent tens of billions of dollars per year. GenoSpace’s target customers are innovators in lab medicine, hospitals and health systems, and research and clinical development organizations. While there are several competitors for individual offerings provided by GenoSpace, the company is unmatched in its cloud-based architecture, comprehensive suite of offerings and experience delivering those offerings to real customers.
How your company differentiates itself from the competition
GenoSpace is differentiated based on several factors related to its approach to deployment, its breadth of offerings, its experience and expertise in genomics and its track record with commercial reference customers. GenoSpace delivers its offerings as a cloud-based software service, which provides a number of performance and deployment advantages for its customers. The company has developed a full suite of data integration, data security, content curation, interpretation, reporting, analytics, collaboration and data capture offerings. These enable organizations with multiple needs and user types to capture the most benefit for their various uses of genomic and other biomedical data.
The company has the strongest track record of deploying for R&D, lab medicine and clinical care customers in the market. GenoSpace has full commercial deployments across many different customers including, one of the most innovative research organizations in the world, the largest physician-owned pathology group in the U.S., and a health system with one of the largest data sets of whole-genome and clinical data. In concert, these elements provide significant differentiation.
GenoSpace tailors its customer contracts based on the needs of the customer, and can provide customers with contracts based on a combination of subscription services, professional services, and usage-based contracts.
GenoSpace is focused on building on its customer successes to expand the number of innovative organizations that are powered by GenoSpace. The company also is focused on continuing to tackle difficult and impactful challenges with its customers and partners. To accomplish these goals, GenoSpace is always interested in hearing from talented candidates in software engineering, implementation, interactive design and business development (please visit careers.genospace.com).
Bootstrap or investors? Why?
Initially, GenoSpace was predominantly funded by its customer contracts. After establishing initial commercial success, the company raised capital to expand on its initial successes and grow the business.
GenoSpace raised growth capital from Thomson Reuters in August 2014.
Number of full-time employees